5Fisher M, Paganini-Hill A, Martin A, et al. Carotid plaque pathology: thrombosis, ulceration, and stroke pathogenesis[J]. Stroke,2005,36(2) :253-257.
6Russell DA, Wijeyaratne SM, Gough MJ. Changes in carotid plaque echomorphology with time since a neurologic event[J]. J Vasc Surg,2007,45(2) :367-372.
7Ding S, Zhang M, Zhao Y, et al. The role of carotid plaque vulnerability and inflammation in the pathogenesis of acute ischemic stroke [J]. Am J Med Sci,2008,336(1) :27-31.
8Peeters W, Hellings WE, de Kleijn DP, et al. Carotid atherosclerotic plaques stabilize after stroke: insights into the natural process of atherosclerotic plaque stabilization [J]. Arterioscler Thromb Vasc Biol,2009,29(1):128-133.
6[9]Pignoli P,Tremoli E,Poli A,et al.Intimai plusmedial thickness of the arterial wall:a direct measurement with ultrasound imaging[J].Circulation,1986,74:1399.
7[10]BotsML,Hofman A,Grobbee DE.Increased conmon carotid intimamedia thickness.Adaptive response or a refleetion of atherosclerosis[J].Stroke,1997,28(12):2442-2247.
8Jander S, Sitzer M, Wendt A, et al. Expression of tissue factor in high-grade carotid artery stenosis: association with plaque destabilization[J]. Stroke, 2001,32(4) :850-854.
9Suwanwela NC,Chutinetr A. Risk Factors for atherosclerosis of cervicocerebral arteries, intracranial versus extracranial [J]. Neuroepidemiology,2003,22(1) :37-40.
5Weimar C, Mieck T, Buchthal J, et al. Neurologie worsening during the acute phase of ischemic stroke[J]. Arch Neurol, 2005,62(3) :393-397.
6Anonymous. CAST: randomised placebo controlled trial of early aspirin use in 20, 000 patients with acute ischaemie stroke. CAST (Chinese Acute Stroke Trial ) Collaborative Group[J]. Lancet, 1997,349(9066) : 1641- 1649.
7Anonymous. The randomized trial of international Stroke Trial ( IST ): aspirin, subcutaneous heparin, both, or neither among 19 435 patients with acute ischemic stroke. International Stroke Trial Group[J]. I.ancet,1997,349(9065): 1569-1581.
8Kennedy J, Hill MD, Ryckborst KJ, et al. Fast assessment of stroke and transient ischemic attack to prevent early recurrent (FASTER):a randomized controlled pilot trial[J]. Lancet Neurol, 2007,6 ( 11 ) : 961-969.
9Shuaib A, Yang Y, Nakada MT, et al. Glycoprotein II b/III a antagonist, murine 7E3 F (ab') 2, and tissue plasminogen activator in focal ischemia: evaluation of efficacy and risk of hemorrhage with combination therapy[J]. J Cereb Blood Flow Metab, 2002,22 (2) : 215-222.
10Meada M,Moriguchi A, Mihara K,et al. FK419,a nonpeptide platelet glycoprotein II b/III a antagonist, ameliorates brain infarction associated with thrombotic focal cerebral ischemia in monkeys: comparison with tissue plasminogen activator[J]. J Cereb Blood Flow Metab,2005,25( 1 ) :108-118.
